Beam Therapeutics (BEAM) has filed a prospectus for an IPO of 6.25M common shares at $15 – 17 per share.
The gene editor says its proprietary technology
is more precise than CRISPR, Zinc Fingers, Arcuses and TAL Nucleases
since it targets a single base, thereby avoiding making a
double-stranded break in the DNA.
https://seekingalpha.com/news/3534741-beam-therapeutics-sets-ipo-terms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.